
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Soligenix Inc (SNGX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SNGX (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $35
1 Year Target Price $35
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.55% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.60M USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 1 | Beta 1.96 | 52 Weeks Range 1.09 - 5.40 | Updated Date 08/15/2025 |
52 Weeks Range 1.09 - 5.40 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -454073.83% |
Management Effectiveness
Return on Assets (TTM) -84.11% | Return on Equity (TTM) -437.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2379131 | Price to Sales(TTM) 4097.86 |
Enterprise Value 2379131 | Price to Sales(TTM) 4097.86 | ||
Enterprise Value to Revenue 1.87 | Enterprise Value to EBITDA -0.12 | Shares Outstanding 3264350 | Shares Floating 3263693 |
Shares Outstanding 3264350 | Shares Floating 3263693 | ||
Percent Insiders 0.02 | Percent Institutions 5.02 |
Upturn AI SWOT
Soligenix Inc

Company Overview
History and Background
Soligenix, Inc. was founded in 2003. The company focuses on developing and commercializing products to treat rare diseases where there is an unmet need. It has evolved from focusing on biodefense vaccines to including a broader pipeline of rare disease therapeutics.
Core Business Areas
- Dermatology: Soligenix is developing HyBryteu2122 (SGX301 or synthetic hypericin) as a potential first-in-class treatment for cutaneous T-cell lymphoma (CTCL).
- Gastroenterology: SGX302 (oral beclomethasone 17,21-dipropionate (BDP) is in development for the prevention of acute gastrointestinal graft-versus-host disease (GI GVHD) after allogeneic hematopoietic stem cell transplantation.
- Vaccines/Biodefense: Soligenix is also developing vaccines and therapeutics for biodefense purposes, including RiVaxu00ae, a ricin toxin vaccine and CiVaxu2122, a heat stable COVID-19 vaccine.
Leadership and Structure
Christopher J. Schaber, PhD is the President and CEO. The company has a typical corporate structure with a board of directors and executive management team overseeing various departments such as R&D, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- HyBryte (SGX301): HyBryte is a potential first-in-class treatment for cutaneous T-cell lymphoma (CTCL). Market share is currently N/A as the product is still under regulatory review for marketing approval. Competitors: Valchlor (mechlorethamine), Bexarotene.
- SGX302 (oral BDP): SGX302 (oral beclomethasone 17,21-dipropionate (BDP) is in development for the prevention of acute gastrointestinal graft-versus-host disease (GI GVHD) after allogeneic hematopoietic stem cell transplantation. Market share is currently N/A as the product is still under development. Competitors: Corticosteroids, immunosuppressants.
- RiVax: RiVax is a ricin toxin vaccine candidate for biodefense purposes. Market share is currently N/A as the product is still under development. Competitors: Emergent BioSolutions.
- CiVax: CiVax is a heat stable COVID-19 vaccine. Market share is currently N/A as the product is still under development. Competitors: Pfizer, Moderna, Novavax.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The rare disease market, in particular, is attracting increasing attention due to favorable regulatory incentives and pricing power.
Positioning
Soligenix is positioned as a specialty pharmaceutical company focused on developing and commercializing niche products in rare diseases. Its competitive advantage lies in its proprietary technologies and targeted approach to addressing unmet medical needs.
Total Addressable Market (TAM)
The TAM for CTCL, where HyBryte is being developed, is estimated to be significant (hundreds of millions of USD). The TAM for GI GVHD is also substantial. Soligenix is positioned to capture a share of these markets upon successful commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary technologies
- Focus on rare diseases with unmet needs
- Experienced management team
- Diversified product pipeline
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials and regulatory approvals
- Lack of commercial infrastructure
- History of operating losses
Opportunities
- Fast-track regulatory pathways for rare diseases
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Potential for orphan drug designation
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Generic erosion of marketed products
Competitors and Market Share
Key Competitors
- VRX
- MRK
- BMY
- TEVA
Competitive Landscape
Soligenix faces significant competition from established pharmaceutical companies with greater financial resources and commercial infrastructure. Its success depends on its ability to differentiate its products and secure regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the developmental stage of the company's product pipeline.
Future Projections: Future growth is dependent on the successful commercialization of HyBryte and other pipeline products. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing HyBryte through regulatory review and progressing other pipeline programs through clinical development.
Summary
Soligenix is a development-stage biopharmaceutical company focused on rare diseases. Its strengths lie in its niche focus and pipeline, but its weaknesses include limited resources and dependence on clinical success. The company needs to secure partnerships and achieve regulatory approvals to unlock its potential, while keeping an eye on maintaining sufficient cash flow to weather the developmental milestones.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Third-Party Financial Data Providers
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share estimates are based on available data and may not be precise. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Soligenix Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1987-06-15 | Chairman of the Board of Directors, CEO & President Dr. Christopher J. Schaber Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.soligenix.com |
Full time employees 14 | Website https://www.soligenix.com |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.